Cobenfy: animal efficacy model or human cells?

“Xanomeline exhibited antipsychotic-like effects in several animal models of schizophrenia, including conditioned avoidance responding in rodents, psychostimulant-induced hyperactivity in rodents, and scheduled-controlled behavior in rodents and monkeys.”

“The antipsychotic effects of xanomeline were abolished by coadministration of scopolamine, a centrally and peripherally active mAChR antagonist, but not by N-methyl-scopolamine, a peripherally active mAChR antagonist, demonstrating that xanomeline’s antipsychotic effects are likely mediated by its activity at the central mAChRs. The therapeutic efficacy of KarXT for the treatment of schizophrenia was determined in the clinical studies.”